Capecitabine (cape) is registered for the treatment of several tumour enitites including colorectal-, gastric- and breast cancer. It is an orally administered 5-fluorouracil (5-FU) prodrug designed to mimic the pharmacokinetics of infusional 5-FU ([@bib12]). A three-step enzymatic process is necessary to convert cape to the active agent 5-FU ([@bib8]). The final step is mediated by thymidine phosphorylase, an enzyme frequently expressed in tumour tissues ([@bib15]).

In stage III colon cancer patients, cape was shown to have at least equivalent activity when compared with bolus 5-FU/folinic acid ([@bib16]). In patients with metastatic colorectal cancer it was non-inferior to infusional 5-FU in combination with oxaliplatin-based therapy in the first- and second-line treatment ([@bib11]; [@bib2]). Recently, it could be shown that cape can replace 5-FU in the neoadjuvant as well as in the perioperative treatment of patients with locally advanced rectal cancer ([@bib10]; [@bib4]).

Dose modifications and tailoring treatment according to adverse events have a pivotal role in the treatment with cape ([@bib3]). Hand--foot--skin reaction (HFSR) is regarded as one of the most important adverse events of cape. In clinical studies, the incidence of HFSR was 20--60%. Hand-foot-skin reaction has been associated with improved outcome in patients with metastatic breast cancer ([@bib14]), and *post hoc* analyses of the X-ACT and CIOX trials ([@bib13]; [@bib16]) suggest that the occurrence of HFSR was associated with better outcome as well.

Here, we sought to explore the potential association of HFSR with disease/progression-free (PFS) and overall survival (OS) in German patients with colorectal cancer treated in two prospective randomised trials. Moreover, we were interested in the time course of HFSR and in potential associations with clinical factors as well as with other toxicities.

Materials and methods
=====================

In this explorative analysis, patient data of two randomised trials was pooled to evaluate the predictive value of cape-induced HFSR. Therefore, data from a randomised non-inferiority phase III trial ([@bib4]) investigating the efficacy of cape in comparison with 5-FU for the perioperative chemoradiotherapy (CRT) of locally advanced rectal cancer (Mannheim rectal cancer trial) and data from a randomised phase II trial ([@bib9]) investigating toxicity and efficacy of CAPOX (cape plus oxaliplatin) and cetuximab *vs* CAPIRI (cape plus irinotecan) plus cetuximab in the treatment of metastatic colorectal cancer (CIOX trial) were analysed together.

Both trials have already been published as full reports ([@bib9]; [@bib4]). Briefly, patients in the rectal cancer trial received six cycles of cape including five cycles with a daily cumulative dose of 2500 mg m^−2^ cape on days 1--14 given in two equal amounts followed by a 1-week rest period. During radiotherapy, dose was reduced to 1650 mg m^−2^ per day. Patients could be treated in the adjuvant as well as in the neoadjuvant setting. Toxicity was evaluated every cycle using the NCI-CTCAE (National Cancer Institute Common Toxicity Criteria of Adverse Events) criteria version 2.0. Dose reduction due to toxicity was done according to the manufacturers\' recommendation. Between 2002 and 2007, a total of 197 patients were randomised to cape treatment within the rectal cancer trial. Disease-free survival (DFS) and OS were defined by the time from randomisation to the date of disease recurrence (metastasis or local recurrence) and date of death, respectively.

Within the CIOX trial, two different doses of cape were administered depending on the chemotherapy combination partner. In the CAPOX plus cetuximab arm, a daily dose of 2000, mg m^−2^ cape was given in two equal amounts on days 1--14 and combined with intravenous infusion of 130 mg m^−2^ oxaliplatin on day 1. This was repeated on day 22. Patients receiving cape in the combination with irinotecan were scheduled to receive a daily dose of 1600 mg m^−2^ cape in two equal amounts on day 1--14 along with 200 mg m^−2^ irinotecan on day 1. Treatment was repeated on day 22. In both treatment arms, 250 mg m^−2^ cetuximab was given weekly, starting with a loading dose of 400 mg m^−2^. Between 2004 and 2006, a total of 177 patients received cape within the CIOX trial and were evaluable for toxicity. Toxicity was evaluated every cycle using NCI-CTCAE criteria version 3.0. Dose reduction due to HFSR was done according to the manufacturers\' recommendations. Progression-free survival was evaluated with consistent imaging techniques (CT or MRI) every two cycles (6 weeks). Progression-free survival and OS were calculated from the time of randomisation to the date of progression and date of death, respectively.

Evaluation of HFSR
------------------

Hand--foot--skin reaction was evaluated using the NCI-CTCAE criteria at any cycle. NCI-CTCAE version 2.0 and 3.0 do not differ with regard to graduation of HFSR. Therefore, HFSR data of both clinical trials could be analysed in a pooled analysis. For statistical analyses, the patient cohort without any sign of HFSR (grade 0) was compared with the group showing any sign of HFSR (grade 1--3). Early HFSR was defined by the appearance of any HFSR during the first two cycles of cape treatment. To evaluate the association between the occurrence of HFSR and survival times, OS, DFS- and PFS data of both trials were merged and analysed together.

Statistics
----------

Within an exploratory analysis the patient cohorts were compared using Fisher\'s exact test, *χ*^2^-test for proportions and Mann--Whitney *U*-test for continuous variables. Progression-free survival/DFS and OS were determined using the Kaplan--Meier method and log-rank testing.

To compare the impact of different factors on PFS and OS a multivariate Cox proportional hazard regression analysis was performed and corresponding hazard ratios were tested using the Wald test. The association of clinical features to predict HFSR was quantified by using multivariate logistic regression models where the corresponding odds ratios were tested by the Wald test.

All statistical tests were two-sided and a *P*-value \<0.05 was considered as statistically significant. The level of significance was corrected for multiple testing using Bonferronis' correction. Accordingly, a *P*-value of \<0.0125 for haematological toxicities and a *P*-value of \<0.01 for non-haematological toxicities was regarded as statistically significant. R (version 2.11.1, R Foundation, Vienna, Austria) and SPSS PASW 18.0 (SPSS Inc., Chicago, IL, USA) software were used for all statistical analyses.

Results
=======

Patient characteristics
-----------------------

Pooled data on toxicity of 374 patients (177 from Arbeitsgemeinschaft für Internistische Onkologie (AIO) CRC-0104 study, 197 from Mannheim rectum trial) was available. Median age of all patients was 63 years (range, 30--85 years), *n*=77 patients (20.6%) were aged ⩾70 years. A total of *n*=358 patients (95.7%) had an ECOG performance status of zero or one, and *n*=256 patients (68.5%) were male.

Regarding all patients, *n*=111 (29.7%) reported any grade HFSR. The grades were distributed as follows: grade 1 *n*=43 (11.5%), grade 2 *n*=52 (13.6%), grade 3 *n*=14 (3.7%), not specified *n*=2 (0.5%). Cumulative occurrence of HFSR is shown in [Figure 1](#fig1){ref-type="fig"}, indicating that HFSR occurs as an early event in most patients during treatment with cape. Early HFSR was observed in 56 (50.9%) of patients developing HFSR at any time, and 75% of patients developed HFSR during the first four cycles of treatment.

Looking at patients\' characteristics ([Table 1](#tbl1){ref-type="table"}) no significant differences with regard to age, gender, ECOG performance status or UICC stage between the patient cohorts were found.

Correlation of HFSR and survival
--------------------------------

Patients developing HFSR had significantly longer survival times, irrespectively of the UICC stage ([Table 2](#tbl2){ref-type="table"}). For the combined analysis of DFS and PFS, patients with HFSR had median survival times of 29.0 months (95% CI: 0.0--58.5 months) compared with 11.4 months (95% CI: 7.1--15.7 months) (log-rank *P*=0.015; HR: 0.69) in patients without HFSR ([Figure 2A](#fig2){ref-type="fig"}). Similar results could be observed for median OS: 75.8 months (95% CI not applicable) (HFSR grade 1--3) *vs* 41.0 months (95% CI: 31.0--51.0 months) (HFSR grade 0) (log-rank *P*\<0.001; HR 0.56) ([Figure 2B](#fig2){ref-type="fig"}). Within the patient cohort that developed HFSR at any grade, no significant difference in survival was seen between those developing HFSR within the two cycles of treatment (early HFSR) and those with later onset of HFSR ([Figure 3A and B](#fig3){ref-type="fig"}). Owing to crossing survival curves, no log-rank correlation analyses has been performed.

In multivariate Cox regression analysis, the occurrence of HFSR adjusted for UICC, ECOG performance status and age was identified to be a strong predictor for longer survival (DFS/PFS: HR 0.57 (95% CI: 0.42--0.77); *P*\<0.001; OS: HR 0.54 (95% CI: 0.38--0.77); *P*=0.001). As expected, higher UICC stage, worse ECOG performance status and older age were significant parameters for shorter OS ([Figure 4](#fig4){ref-type="fig"}).

Clinical factors predicting HFSR
--------------------------------

In multivariate logistic regression analyses, baseline patient characteristics were used to detect predictors for the occurrence of HFSR. As depicted in [Figure 5](#fig5){ref-type="fig"}, no significance for age, gender, ECOG performance status or UICC stage was established.

Correlation of HFSR with other toxicities
-----------------------------------------

Next to skin toxicity, other haematological and non-haematological toxicities were recorded. As a first step, the incidence of grade 3 and grade 4 toxicities within the group of patients developing HFSR were compared with the group not showing HFSR. A significant difference in the frequency of grade 3--4 toxicities could neither be observed with regard to haematological nor to non-haematological toxicities ([Table 3](#tbl3){ref-type="table"}).

Further analyses exploring all grades of haematological and non-haematological toxicities revealed a significant difference with higher observed frequency of diarrhoea, stomatitis/mucositis and fatigue in patients with HFSR ([Table 4](#tbl4){ref-type="table"}). The frequency of haematological adverse events was not higher in the HFSR group.

Discussion
==========

The present analysis confirms previous reports that HFSR is a predictor of improved survival in patients with colorectal cancer ([@bib13]; [@bib16]): Using multivariate analysis it could be demonstrated that both, PFS/DFS and OS data was significantly better in patients developing HFSR. The time point of the development of HFSR was not associated with improved survival. Patients developing HFSR during the first two cycles of treatment had no better outcome than patients with late HFSR. Baseline patient characteristics such as age, gender, ECOG status and UICC stage were not found to be associated with the risk of developing a HFSR. This observation is in line with other reports ([@bib19]). Our analysis revealed that the development of all-grade mucosal toxicities such as stomatitis/mucositis and diarrhoea was associated with the risk of developing HFSR, whereas no association with haematological toxicities and HFSR was noticed. This may only in part be explained by higher plasma concentrations because one would expect that higher plasma levels of cape and its metabolites would also impact on the probability of developing other toxicities. One might speculate on the higher susceptibility of the mucosal tissue to increased concentrations of the drug compared with haematopoiesis. This observation, however, deserves further analysis in other studies.

Compared with earlier reports, the percentage of all-grade HFSR at first glance appears to be lower in the present analysis. For instance, in the X-ACT trial the rate of HFSR was almost twice as high (*n*=613 out of 1004 patients corresponding to 61.1%) ([@bib17]). This might be explained by the lower doses of cape used in the CIOX trial (1600 or 2000, mg m^−2^) in comparison with the X-ACT trial (2500 mg m^−2^). Moreover, in the rectal cancer trial the CRT cycle comprised a daily dose of 1650 mg m^−2^ resulting in a decreased daily exposure during a 6-week period. Looking at combination chemotherapy, trials such as the NO16966 trial including XELOX patients who received cape 2000, mg m^−2^ a lower rate of HFSR was noticed as well (*n*=198/655 patients corresponding to 30.2%) ([@bib1]). Thus, the rate of HFSR reported in the present analysis is comparable to other trials. The same applies to the time course of development of HFSR. About 75.5% of patients in the present analysis developed HFSR during the first four cycles of chemotherapy. This corresponds favourably to data recently published by Chinese investigators who showed that about 80% of cape patients developing HFSR had experienced this adverse event by cycle 4 (data extrapolated from Kaplan--Meier plot; cf. [@bib19].

With the exception of one trial, clinical studies have failed to demonstrate a benefit of supportive prophylactic measures and treatments of cape-related HFSR. Pyridoxine was ineffective in a Korean randomised trial in 360 patients ([@bib5]). Similarly, the topical use of a urea/lactic-acid-based keratolytic agent in a randomised double-blind trial in 137 patients treated with cape in the United States of America was found to be ineffective ([@bib18]). Recently, celecoxib at a dose of 200 mg twice a day was reported to reduce the overall incidence of HFSR from 74.6 to 57.4% in Chinese patients receiving XELOX or cape monotherapy ([@bib19]). Several methodological shortcomings of the trial (for instance: no patient-reported outcome data, no efficacy data, study conducted at a single centre), and the uncertainty if the results from an Asian patient group may be transferred to Caucasian patients along with potential cardiovascular risks of celecoxib raise doubts as to whether these results should change current clinical practice. Thus, dose reduction and treatment interruption remain the definitive therapies for HFSR.

The primary problem in the prevention of HFSR is that the pathogenesis of HFSR has not been fully elucidated yet. Hand--foot--skin reaction is frequently considered as a type of inflammation ([@bib3]), but recent data indicate that HFSR may be caused by a reduction in the antioxidative potential of the skin due to intensive radical formation. The latter was demonstrated to be caused by the excretion of parts of cytotoxic agents with the sweat onto the skin surface spreading there homogeneously and penetrating into the stratum corneum. This led to disturbance preferably in 'vulnerable\' body areas with thick stratum corneum such as the palm and the planta ([@bib6]; [@bib7]). Having said, this may point towards new prophylactic measures for the prevention of HFSR using antioxidant containing ointments with high radical protection factor. The German AIO has recently started a randomised trial investigating a new topical antioxidative cream (Mapisal, medac GmbH, Wedel, Germany), which has been licensed as medical device in Germany.

In summary, our results indicate that the development of HFSR may be regarded as independent clinical predictor of improved survival in patients with colorectal cancer regardless of the time point of HFSR development. Testing individual dose optimisation or titration of cape according to the development HFSR may therefore be an appealing strategy for future studies.

We are indebted to Roche Pharma, Germany for providing a grant to enable publication of this work as 'open acces\' publication.

![Cumulative occurrence of HFSR by cycle indicated as proportion of all patients included in analysis. Abbreviation: HFS=hand--foot skin reaction](bjc2012434f1){#fig1}

![(**A**) Progression-free/disease-free survival according to the development of HFSR. (**B**) Overall survival according to the development of HFSR.](bjc2012434f2){#fig2}

![(**A**) Progression-free/disease-free survival according to the time point of development of HFSR ('early\' *vs* 'late\' HFSR). (**B**) Overall survival according to the development of HFSR ('early\' *vs* 'late\' HFSR).](bjc2012434f3){#fig3}

![Hazard ratio (HR) to predict PFS/DFS and OS. Abbreviations: age=continuous variable; ECOG ½=Eastern Cooperative Oncology Group performance status ½ gender: male=1; HFS=hand--foot--skin reaction; UICC IV=union contre le cancer stage IV; \*=Wald correlation test.](bjc2012434f4){#fig4}

![Odds ratio (OR) to predict HFSR. Abbreviations: age=continuous variable; ECOG ½=Eastern Cooperative Oncology Group performance status ½ gender: male=1; UICC IV=union contre le cancer stage IV; \*=Wald correlation test.](bjc2012434f5){#fig5}

###### Baseline characteristics (*n*=374 patients)

                             **HFSR grade 0 (*****n*****=263)**   **HFSR grade 1--3 (*****n*****=111)**   ***P***
  -------------------------- ------------------------------------ --------------------------------------- ----------------------------------
  Median age (range) years   63 (30--85)                          64 (30--80)                             0.705[a](#t1-fn2){ref-type="fn"}
  Age \>65 years, *n* (%)    111 (68.5)                           51 (31.5)                               0.568[b](#t1-fn3){ref-type="fn"}
  Age \>70 years, *n* (%)    57 (74.0)                            20 (26.0)                               0.485[b](#t1-fn3){ref-type="fn"}
                                                                                                           
  *Gender*                                                                                                
   Male, *n* (%)             186 (72.7)                           70 (27.3)                               0.147[b](#t1-fn3){ref-type="fn"}
   Female, *n* (%)           77 (65.3)                            41 (34.7)                                
                                                                                                           
  *ECOG-PS*                                                                                               
   0, *n* (%)                173 (70.9)                           71 (29.1)                               0.504[c](#t1-fn4){ref-type="fn"}
   1, *n* (%)                66 (67.3)                            32 (32.7)                                
   2, *n* (%)                13 (81.3)                            3 (18.8)                                 
                                                                                                           
  *UICC stage*                                                                                            
   UICC II/III, *n* (%)      135 (68.5)                           62 (31.5)                               0.430[b](#t1-fn3){ref-type="fn"}
   UICC IV, *n* (%)          128 (72.3)                           49 (27.7)                                

Abbreviations: ECOG-PS=Eastern Cooperative Oncology Group performance status; Grade=NCI-CTCAE grade; HFSR=hand--foot--skin reaction; UICC stage=Union Internationale Contre le Cancer stage.

Mann--Whitney *U*-test.

Fisher\'s exact test.

*χ*^2^-test.

###### Survival times in dependence of the occurrence of HFSR

                                                      **HFSR grade 0**    **HFSR grade 1--3**  ***P***[a](#t2-fn2){ref-type="fn"}, **HR (95% CI)**
  -------------------------------------------------- ------------------- --------------------- -----------------------------------------------------
  *UICC II/III*                                            *n*=135              *n*=62          
   DFS[b](#t2-fn3){ref-type="fn"}, months (95% CI)    72.2 (64.9--79.4)    69.4 (61.4--77.3)   0.19, 0.67 (0.37--1.21)
   OS[b](#t2-fn3){ref-type="fn"}, months (95% CI)     79.0 (72.3--85.6)    80.7 (75.5--86.0)   0.016, 0.36 (0.15--0.86)
  *UICC IV*                                                *n*=128              *n*=49          
   PFS, months (95% CI)                                5.6 (4.6--6.4)       9.9 (7.9--11.9)    \<0.0001, 0.59 (0.40--0.87)
   OS, months (95% CI)                                19.7 (15.6--23.8)    32.0 (26.9--37.2)   0.006, 0.54 (0.38--0.75)
  *Pooled data*                                            *n*=263              *n*=111         
   PFS/DFS, months (95% CI)                           11.4 (7.1--15.7)     29.0 (0.0--58.5)    0.015, 0.69 (0.52--0.94)
   OS, months (95% CI)                                41.0 (31.0--51.0)        75.8 (NA)       ⩽0.001, 0.56 (0.40--0.80)

Abbreviations: 95% CI=95% confidence interval; DFS=disease-free survival; Grade=NCI-CTCAE grade; HFSR=hand--foot--skin reaction; HR=hazard ratio; NA=not applicable; OS=overall survival; PFS=progression-free survival; UICC=UICC stage.

Logrank test.

Mean values as median has not been reached.

###### NCI-CTCAE grade 3 and 4 adverse events according to the development of HFSR

                                  **HFSR grade 0,** ***n*** **(%)**   **HFSR grade 1--3,** ***n*** **(%)**   ***P***[a](#t3-fn2){ref-type="fn"}
  ------------------------------- ----------------------------------- -------------------------------------- ------------------------------------
  *Haematologic toxicities*                                                                                  
   Anaemia                        4 (1.7)                             3 (2.7)                                0.428
   Leukocytopenia                 10 (3.8)                            1 (0.9)                                0.185
   Thrombocytopenia               3 (1.1)                             0                                      0.558
   Neutropenic fever              0                                   0                                      NA
                                                                                                              
  *Non-haematologic toxicities*                                                                              
   Nausea                         11 (4.2)                            6 (5.4)                                0.594
   Vomiting                       6 (2.3)                             2 (1.8)                                \>0.99
   Diarrhoea                      35 (13.3)                           17 (15.3)                              0.625
   Stomatitis/mucositis           0                                   2 (1.8)                                0.088
   Fatigue                        10 (3.8)                            5 (4.5)                                0.776

Abbreviations: Grade=NCI-CTCAE grade; HFSR=hand--foot--skin reaction; NA=not applicable.

Fisher\'s exact test.

###### NCI-CTCAE adverse events of any grade according to the development of HFSR

                                    **HFSR grade 0,** ***n*** **(%)**   **HFSR grade 1--3,** ***n*** **(%)**   ***P***[a](#t4-fn2){ref-type="fn"}
  --------------------------------- ----------------------------------- -------------------------------------- ------------------------------------
  *Haematological toxicities*                                                                                  
   Anaemia                          138 (52.5)                          66 (59.5)                              0.256
   Leukocytopenia                   85 (32.3)                           43 (38.7)                              0.236
   Thrombocytopenia                 68 (25.9)                           30 (27.0)                              0.799
   Neutropenic fever                0 (0)                               0 (0)                                  NA
                                                                                                                
  *Non-haematological toxicities*                                                                              
   Nausea                           78 (29.7)                           45 (40.5)                              0.054
   Vomiting                         37 (14.1)                           19 (17.1)                              0.526
   Diarrhoea                        122 (46.4)                          83 (74.8)                              ⩽0.001
   Stomatitis/mucositis             30 (11.4)                           32 (28.8)                              ⩽0.001
   Fatigue                          81 (30.8)                           55 (49.5)                              0.001

Abbreviations: Grade=NCI-CTCAE grade; HFSR=hand--foot--skin reaction.

Fisher\'s exact test.
